OncoMatch

OncoMatch/Clinical Trials/NCT06766643

Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer

Is NCT06766643 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for primary liver cancer.

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06766643Data as of Jun 2026Location: China

A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Demographics

Ages ≤ 75

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: anti-tumor treatment

No previous anti-tumor treatment

Cannot have received: anti-target tumor therapies

Previous treatment with anti-target tumor therapies

Cannot have received: upper abdominal radiotherapy

History of upper abdominal radiotherapy

Lab requirements

Blood counts

ANC ≥ 1.5 × 10^9, platelets ≥ 70 × 10^9, hemoglobin ≥ 80 g/L

Kidney function

serum creatinine < 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL/min

Liver function

bilirubin < 3.0 mg/dL, INR < 1.7, albumin ≥ 2.8 g/dL, AST/ALT < 6

Normal major organ functions, including blood routine tests [absolute neutrophil count (ANC) ≥ 1.5 × 10^9, platelets ≥ 70 × 10^9, hemoglobin ≥ 80 g/L], liver function tests [bilirubin < 3.0 mg/dL, international normalized ratio (INR) < 1.7, albumin ≥ 2.8 g/dL, aspartate transaminase (AST)/alanine transaminase (ALT) < 6], serum creatinine < 1.5 times the upper limit of normal, or creatinine clearance ≥ 60 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06766643 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify